PepGen (PEPG)
(Real Time Quote from BATS)
$8.86 USD
+0.16 (1.84%)
Updated Sep 11, 2024 01:50 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
PepGen, Inc. [PEPG]
Reports for Purchase
Showing records 1 - 20 ( 49 total )
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
A Little PEP(G) In Our Step As We Connect With PEPG Management
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
CONNECT1 Validates Platform Potential-Implications for FREEDOM
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on CONNECT2 As PoC Data Indicates Higher Dosing Might Lead to Higher Dystrophin Expression
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Good Things Come To Those Who Wait; Thoughts On PGNEDO51/ CONNECT-1
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
How Does DMD Drug Development Change Post-Elevidys?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
CONNECTing With Management - Thoughts on Upcoming PGN-EDO51 Readout
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead To Near-Term Data Readout With CONNECT-1
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
CONNECT Can Achieve Clinically Meaningful Dystrophin Expression - Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
PGN-EDODM1 has the Potential to Achieve > 30% Splicing Correction?Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Making CONNECTions With PGN-EDO51 Data Tracking to Mid-2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department